Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD5 | P21918 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859092 | 0.88 | PRMT5 (0.47) | PRMT5WDR77MEN1KMT2AGRIA1 | |
| SCHEMBL13181749 | 0.84 | PRMT5 (0.45) | PRMT5WDR77MEN1KMT2ADRD2 | |
| SCHEMBL11018836 | 0.83 | DRD2 (0.44) | PRMT5WDR77MEN1KMT2ADRD2 | |
| SCHEMBL15504639 | 0.82 | DRD2 (0.47) | PRMT5WDR77DRD2DRD1DRD5 | |
| SCHEMBL14895892 | 0.81 | KDM4E (0.48) | PRMT5WDR77MEN1KMT2ATRPA1 | |
| SCHEMBL27849729 | 0.79 | TRPA1 (0.51) | KMT2ADRD2DRD3TRPA1 | |
| SCHEMBL697731 | 0.79 | SYK (0.45) | PRMT5WDR77MEN1KMT2ATRPA1 | |
| SCHEMBL19739032 | 0.78 | ESR2 (0.51) | PRMT5WDR77 | |
| SCHEMBL3440772 | 0.77 | GRIA1 (0.51) | PRMT5WDR77MEN1KMT2AGRIA1 | |
| SCHEMBL7408640 | 0.76 | TRPA1 (0.49) | MEN1KMT2ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| EP-2051975-B1 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7807693-B2 | Substituted prolinamides, manufacturing, and the use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| EP-2051975-A2 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | Boehringer Ingelheim International GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | US | disclosed |
| WO-2007131982-A2 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | PRMT5 1883/4885WDR77 4560/4885MEN1 4184/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | PRMT5 2489/4885WDR77 2058/4885MEN1 2292/4885 |
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | PPID, PREP, P4HA1 | PRMT5 234/4885WDR77 4516/4885MEN1 1199/4885 |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | PRMT5 2489/4885WDR77 2058/4885MEN1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.